Why is Foghorn Therapeutics stock plunging today?
Foghorn Therapeutics' stock plunged 31.2% to $2.01 after it and Eli Lilly ended their collaboration due to insufficient clinical efficacy in a Phase 1 trial. Analysts downgraded the stock and cut price targets, citing the loss of a key partnership and a 40% workforce reduction. The company's pipeline is now entirely preclinical, raising concerns about its future.
How this was made
The 30-second read
Why it matters
The abrupt termination of the partnership and subsequent analyst downgrades have caused a steep price decline, highlighting heightened execution risk for early‑stage biotech collaborations.
Market read
The news is a primary corporate event for FHTX, driving a significant intraday move and prompting analyst action, making it relevant for short‑term traders.
What to watch
Potential cash runway extension to 2029 and a fully preclinical pipeline could provide upside if capital is raised.
Background
Foghorn Therapeutics (FHTX) is a pre‑clinical biotech that relied heavily on its collaboration with Eli Lilly for SMARCA2/4 programs.
Ticker impact
Foghorn Therapeutics announced it and Eli Lilly will not advance the FHD-909 program and ended their collaboration, triggering multiple analyst downgrades and a 31.2% share plunge.
downward pressure as analysts cut targets and investors reassess near‑term prospects
Analyst downgrades and a 31% intraday drop indicate strong bearish bias; no offsetting catalyst is present.
Market effects
Biotech sector may see broader risk aversion toward early‑stage partnership failures.
U.S. market largely unaffected; the move is isolated to FHTX.
Limited to investors tracking biotech collaboration pipelines.
Counterpoint
If FHTX can secure a new partner or fund its EP300 program, the stock may be oversold.
Key entities
- companyFoghorn Therapeutics
US‑listed biotech (NASDAQ: FHTX) focused on epigenetic targets.
- companyEli Lilly
Pharma partner that ended collaboration with FHTX.